#Denmark #Copenhagen #Adcendo ApS #ADCE-D01 #soft tissue sarcoma

Adcendo ApS to Reveal Innovative ADC Data at Major Cancer Symposium

In an eagerly awaited event, Adcendo ApS, a pioneering biotech firm, is set to present its groundbreaking findings on the ADCE-D01 drug at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. This presentation will take place in Barcelona, Spain, from November 18 to 20, 2026. Within the field of oncology, finding effective treatments for advanced soft tissue sarcoma is crucial, and Adcendo's innovative approach promises to shed light on new possible solutions for patients in dire need of effective therapies.

Overview of Presentation

Adcendo's engaging plenary session will be led by Dr. Patrick Schöffski from the University Hospitals Leuven and KU Leuven, Belgium. The presentation is titled, "A novel antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein in previously treated patients with advanced soft tissue sarcoma: emerging clinical results from the phase 1 ADCElerate1 study (NCT06797999)." The oral presentation is scheduled for Thursday, November 19, 2026, at 10:00 a.m. CET (4:00 a.m. ET), during Session 3 – Proffered Papers Clinical Trials, with abstract number 4LBA.

During this session, Adcendo will unveil the initial clinical data from the ongoing ADCElerate1 trial, which evaluates the effectiveness of ADCE-D01—a first-in-class antibody-drug conjugate (ADC)—against the novel target known as uPARAP. This new treatment could revolutionize the way we approach soft tissue sarcomas.

About Adcendo ApS

Headquartered in Copenhagen, Denmark, with additional operations in Boston, Massachusetts, Adcendo ApS is dedicated to developing a cutting-edge pipeline of differentiated antibody-drug conjugates aimed at treating high-unmet need cancers. The company adopts a disease- and target-driven strategy, striking a balance between efficacy and tolerability in its innovative designs. Adcendo's experienced biopharma leadership has successfully pushed multiple ADCs towards approval and remains committed to integrating profound insights into target biology and disease understanding throughout their development.

Currently, Adcendo is advancing three notable ADC programs targeting various high-unmet need indications, including soft tissue sarcoma, squamous cell cancers, and pancreatic ductal adenocarcinoma, among others. Through their research and clinical insights, Adcendo is poised to contribute significantly to the next generation of cancer therapies.

For those keen on learning more about this trailblazing presentation or the promising developments at Adcendo, please visit Adcendo's website or follow the company on LinkedIn to stay updated on their progress in revolutionizing cancer therapy.

In the rapidly evolving landscape of oncology, events like the EORTC-NCI-AACR symposium highlight the importance of collaboration among researchers and clinicians to explore and validate new treatment pathways. The hope is that Adcendo's latest findings will spark further discussions and research, ultimately leading to improved outcomes for patients battling advanced soft tissue sarcoma and beyond.